Boosting of serum neutralizing activity against the Omicron variant among recovered COVID-19 patients by BNT162b2 and CoronaVac vaccines

SARS-CoV-2 Omicron variant evades immunity from past infection or vaccination and is associated with a greater risk of reinfection among recovered COVID-19 patients. We assessed the serum neutralizing antibody (NAb) activity against Omicron variant (Omicron NAb) among recovered COVID-19 patients wit...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	EBioMedicine 2022-05, Vol.79, p.103986-103986, Article 103986
Hauptverfasser:	Lu, Lu, Chen, Lin-Lei, Zhang, Ricky Rui-Qi, Tsang, Owen Tak-Yin, Chan, Jacky Man-Chun, Tam, Anthony Raymond, Leung, Wai-Shing, Chik, Thomas Shiu-Hong, Lau, Daphne Pui-Ling, Choi, Chris Yau-Chung, Fong, Carol Ho-Yan, Cai, Jian-Piao, Tsoi, Hoi-Wah, Choi, Charlotte Yee-Ki, Zhang, Xiaojuan, Abdullah, Syed Muhammad Umer, Chan, Brian Pui-Chun, Chan, Kwok-Hung, Yuen, Kwok-Yung, Hung, Ivan Fan-Ngai, To, Kelvin Kai-Wang
Format:	Artikel
Sprache:	eng
Schlagworte:	Antibodies, Blocking Antibodies, Neutralizing Antibodies, Viral Beta variant BNT162 Vaccine COVID-19 COVID-19 - prevention & control COVID-19 Vaccines Delta variant Humans Inactivated vaccine mRNA vaccine Neutralizing antibody Omicron variant Prospective Studies SARS-CoV-2 Spike protein receptor binding domain Surrogate neutralizing antibody test
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	SARS-CoV-2 Omicron variant evades immunity from past infection or vaccination and is associated with a greater risk of reinfection among recovered COVID-19 patients. We assessed the serum neutralizing antibody (NAb) activity against Omicron variant (Omicron NAb) among recovered COVID-19 patients with or without vaccination. In this prospective cohort study with 135 recovered COVID-19 patients, we determined the serum NAb titers against ancestral virus or variants using a live virus NAb assay. We used the receiver operating characteristic analysis to determine the optimal cutoff for a commercially-available surrogate NAb assay. Among recovered COVID-19 patients, the serum live virus geometric mean Omicron NAb titer was statistically significantly higher among BNT162b2 recipients compared to non-vaccinated individuals (85.4 vs 5.6,P
ISSN:	2352-3964 2352-3964
DOI:	10.1016/j.ebiom.2022.103986